glp-1 glp-2 dual agonist and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Dual and Triple Gut Peptide

PIB Backgrounder : 01 APR 2026 10:48AM by PIB Delhi Introduction Diabetes is a chronic disease that occurs when the pancreas does not produce adequate insulin, or when the body cannot effectively use the insulin it produces, leading to high blood sugar

2024 May 17 [cited 2025 Oct 21];27(5)

Since sodium/glucose cotransporter-2 (SGLT-2) inhibitor treatment reduces CV events as well (with the effect mainly driven by a reduction in heart failure complications), the individual risk of ischemic or heart failure complications should guide the choice of treatment

Modulating mitochondrial bioenergetics may be an effective treatment for HF since empagliflozin treatment significantly increased the myocardial ATP levels, myocardial mitochondrial complex I activity, and myocardial mitochondrial respiratory control ratio at 6 and 24 h after return of spontaneous circulation (ROSC) [119]

If your plan covers Ozempic for diabetes, the dosing chart shows the titration schedule your doctor would follow